RAPP

Rapport Therapeutics (RAPP)

About Rapport Therapeutics (RAPP)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Details

Daily high

$31.02

Daily low

$28.53

Price at open

$29.37

52 Week High

$42.27

52 Week Low

$6.43

Market cap

1.4B

Dividend yield

0.00%

Volume

268,521

Avg. volume

370,716

P/E ratio

-10.99

Rapport Therapeutics News